<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671708</url>
  </required_header>
  <id_info>
    <org_study_id>IDA+BUCY vs BUCY-AML-2016</org_study_id>
    <nct_id>NCT02671708</nct_id>
  </id_info>
  <brief_title>IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT</brief_title>
  <official_title>Idarubicin+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Intermediate-risk Acute Myeloid Leukemia Undergoing Autologous Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autologous hematopoietic stem cell transplantation (Auto-HSCT) is an effective alternative to
      allogeneic HSCT for intermediate-risk acute myeloid leukemia (AML) without HLA-matched
      donors. At present, the best conditioning regimen for AML undergoing auto-HSCT remains in
      discussion. In this study, the safety and efficacy of IDA+BUCY and BUCY myeloablative
      conditioning regimens in intermediate-risk AML undergoing auto-HSCT are evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Auto-HSCT is an effective alternative to allogeneic HSCT for intermediate-risk AML without
      HLA-matched donors. BUCY conditioning regimen is the standard myeloablative regimen. However,
      auto-HSCT with BUCY conditioning regimen appears to have higher relapse rate. To reduce the
      relapse rate, IDA is added in the conditioning regimen. In this study, the safety and
      efficacy of IDA+BUCY and BUCY myeloablative conditioning regimens in intermediate-risk AML
      patients undergoing auto-HSCT are evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>leukemia relapse rate</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival (DFS)</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transplant-related mortality (TRM)</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Autologous Hematopoietic Stem Cell Transplantation</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Conditioning</condition>
  <arm_group>
    <arm_group_label>IDA+BUCY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For intermediate-risk AML undergoing auto-HSCT，IDA+BUCY conditioning regimen was IDA 15mg/m2/day on days -12 and -10；BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BUCY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For intermediate-risk AML undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days
-3 and -2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin（IDA）</intervention_name>
    <description>Idarubicin was administered at 15mg/m2/day on days -12 and -10.</description>
    <arm_group_label>IDA+BUCY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan (BU)</intervention_name>
    <description>Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.</description>
    <arm_group_label>BUCY</arm_group_label>
    <arm_group_label>IDA+BUCY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (CY)</intervention_name>
    <description>Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.</description>
    <arm_group_label>BUCY</arm_group_label>
    <arm_group_label>IDA+BUCY</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intermediate-risk AML

          -  Achieving CR after one cycle induction,then receiving three cycles of consolidation
             therapy including moderate and high doses of Ara-c combined regimens

          -  With negative MRD before mobilization and collect of peripheral blood stem cells

          -  Without HLA-matched donors (related and unrelated)

          -  Refusal of haploidentical hematopoietic stem cell transplantation

        Exclusion Criteria:

          -  Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood
             pressure)

          -  Patients with any conditions not suitable for the trial (investigators' decision)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifa Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hematology,Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 30, 2016</study_first_submitted>
  <study_first_submitted_qc>January 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

